The Experts below are selected from a list of 26619 Experts worldwide ranked by ideXlab platform
Daniel Teupser - One of the best experts on this subject based on the ideXlab platform.
-
Impact of the bioresorbable vascular Scaffold Surface area on on-treatment platelet reactivity.
Platelets, 2016Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:While promising data with the novel bioresorbable vascular Scaffold (BVS) are accumulating, signals of Scaffold thrombosis (ST) were noted in recent reports. We aimed to assess the relationship between the total Surface area (TSA) of implanted everolimus-eluting BVSs and the on-treatment adenosine diphosphate (ADP)-induced platelet reactivity in patients undergoing percutaneous coronary intervention (PCI). 202 consecutive patients undergoing BVS implantation and platelet function testing were included. For investigating the impact of the Scaffold Surface on platelet reactivity, patients were stratified into two groups regarding the median BVS TSA. The on-treatment ADP-induced platelet reactivity was determined with the Multiplate analyzer and 30-day follow-up was available in 98% of patients. ADP-induced platelet aggregation values (median, [IQR]) did not differ between the two study groups (12.0 [9.0-19.0] U for patients with TSA > 1.39 cm(2) and 13.0 [9.0-19.5] U for patients with TSA ≤ 1.39 cm(2); p = 0.69). No correlation was observed between the BVS TSA and levels of platelet reactivity (Spearman rank correlation = -0.10, p = 0.16). At 30 days after PCI, two early STs (1%) were documented. Thus, in patients on a dual antiplatelet treatment regimen following BVS implantation, the extent of blood-to-BVS contact Surface does not negatively affect levels of on-treatment platelet reactivity.
-
IMPACT OF THE ABSORB BIORESORBABLE VASCULAR Scaffold Surface AREA ON ON-TREATMENT PLATELET REACTIVITY
Journal of the American College of Cardiology, 2015Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:Bioresorbable vascular Scaffolds (BVS) promise to address pending issues of current-generation stents. While promising data of this novel platform is accumulating, signals of Scaffold thrombosis (ST) were noted in recent registry data. Our study aimed to determine whether such signals could be
Lisa Gross - One of the best experts on this subject based on the ideXlab platform.
-
Impact of the bioresorbable vascular Scaffold Surface area on on-treatment platelet reactivity.
Platelets, 2016Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:While promising data with the novel bioresorbable vascular Scaffold (BVS) are accumulating, signals of Scaffold thrombosis (ST) were noted in recent reports. We aimed to assess the relationship between the total Surface area (TSA) of implanted everolimus-eluting BVSs and the on-treatment adenosine diphosphate (ADP)-induced platelet reactivity in patients undergoing percutaneous coronary intervention (PCI). 202 consecutive patients undergoing BVS implantation and platelet function testing were included. For investigating the impact of the Scaffold Surface on platelet reactivity, patients were stratified into two groups regarding the median BVS TSA. The on-treatment ADP-induced platelet reactivity was determined with the Multiplate analyzer and 30-day follow-up was available in 98% of patients. ADP-induced platelet aggregation values (median, [IQR]) did not differ between the two study groups (12.0 [9.0-19.0] U for patients with TSA > 1.39 cm(2) and 13.0 [9.0-19.5] U for patients with TSA ≤ 1.39 cm(2); p = 0.69). No correlation was observed between the BVS TSA and levels of platelet reactivity (Spearman rank correlation = -0.10, p = 0.16). At 30 days after PCI, two early STs (1%) were documented. Thus, in patients on a dual antiplatelet treatment regimen following BVS implantation, the extent of blood-to-BVS contact Surface does not negatively affect levels of on-treatment platelet reactivity.
-
IMPACT OF THE ABSORB BIORESORBABLE VASCULAR Scaffold Surface AREA ON ON-TREATMENT PLATELET REACTIVITY
Journal of the American College of Cardiology, 2015Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:Bioresorbable vascular Scaffolds (BVS) promise to address pending issues of current-generation stents. While promising data of this novel platform is accumulating, signals of Scaffold thrombosis (ST) were noted in recent registry data. Our study aimed to determine whether such signals could be
Martin Orban - One of the best experts on this subject based on the ideXlab platform.
-
Impact of the bioresorbable vascular Scaffold Surface area on on-treatment platelet reactivity.
Platelets, 2016Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:While promising data with the novel bioresorbable vascular Scaffold (BVS) are accumulating, signals of Scaffold thrombosis (ST) were noted in recent reports. We aimed to assess the relationship between the total Surface area (TSA) of implanted everolimus-eluting BVSs and the on-treatment adenosine diphosphate (ADP)-induced platelet reactivity in patients undergoing percutaneous coronary intervention (PCI). 202 consecutive patients undergoing BVS implantation and platelet function testing were included. For investigating the impact of the Scaffold Surface on platelet reactivity, patients were stratified into two groups regarding the median BVS TSA. The on-treatment ADP-induced platelet reactivity was determined with the Multiplate analyzer and 30-day follow-up was available in 98% of patients. ADP-induced platelet aggregation values (median, [IQR]) did not differ between the two study groups (12.0 [9.0-19.0] U for patients with TSA > 1.39 cm(2) and 13.0 [9.0-19.5] U for patients with TSA ≤ 1.39 cm(2); p = 0.69). No correlation was observed between the BVS TSA and levels of platelet reactivity (Spearman rank correlation = -0.10, p = 0.16). At 30 days after PCI, two early STs (1%) were documented. Thus, in patients on a dual antiplatelet treatment regimen following BVS implantation, the extent of blood-to-BVS contact Surface does not negatively affect levels of on-treatment platelet reactivity.
-
IMPACT OF THE ABSORB BIORESORBABLE VASCULAR Scaffold Surface AREA ON ON-TREATMENT PLATELET REACTIVITY
Journal of the American College of Cardiology, 2015Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:Bioresorbable vascular Scaffolds (BVS) promise to address pending issues of current-generation stents. While promising data of this novel platform is accumulating, signals of Scaffold thrombosis (ST) were noted in recent registry data. Our study aimed to determine whether such signals could be
Dirk Sibbing - One of the best experts on this subject based on the ideXlab platform.
-
Impact of the bioresorbable vascular Scaffold Surface area on on-treatment platelet reactivity.
Platelets, 2016Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:While promising data with the novel bioresorbable vascular Scaffold (BVS) are accumulating, signals of Scaffold thrombosis (ST) were noted in recent reports. We aimed to assess the relationship between the total Surface area (TSA) of implanted everolimus-eluting BVSs and the on-treatment adenosine diphosphate (ADP)-induced platelet reactivity in patients undergoing percutaneous coronary intervention (PCI). 202 consecutive patients undergoing BVS implantation and platelet function testing were included. For investigating the impact of the Scaffold Surface on platelet reactivity, patients were stratified into two groups regarding the median BVS TSA. The on-treatment ADP-induced platelet reactivity was determined with the Multiplate analyzer and 30-day follow-up was available in 98% of patients. ADP-induced platelet aggregation values (median, [IQR]) did not differ between the two study groups (12.0 [9.0-19.0] U for patients with TSA > 1.39 cm(2) and 13.0 [9.0-19.5] U for patients with TSA ≤ 1.39 cm(2); p = 0.69). No correlation was observed between the BVS TSA and levels of platelet reactivity (Spearman rank correlation = -0.10, p = 0.16). At 30 days after PCI, two early STs (1%) were documented. Thus, in patients on a dual antiplatelet treatment regimen following BVS implantation, the extent of blood-to-BVS contact Surface does not negatively affect levels of on-treatment platelet reactivity.
-
IMPACT OF THE ABSORB BIORESORBABLE VASCULAR Scaffold Surface AREA ON ON-TREATMENT PLATELET REACTIVITY
Journal of the American College of Cardiology, 2015Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:Bioresorbable vascular Scaffolds (BVS) promise to address pending issues of current-generation stents. While promising data of this novel platform is accumulating, signals of Scaffold thrombosis (ST) were noted in recent registry data. Our study aimed to determine whether such signals could be
Madeleine Eickhoff - One of the best experts on this subject based on the ideXlab platform.
-
Impact of the bioresorbable vascular Scaffold Surface area on on-treatment platelet reactivity.
Platelets, 2016Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:While promising data with the novel bioresorbable vascular Scaffold (BVS) are accumulating, signals of Scaffold thrombosis (ST) were noted in recent reports. We aimed to assess the relationship between the total Surface area (TSA) of implanted everolimus-eluting BVSs and the on-treatment adenosine diphosphate (ADP)-induced platelet reactivity in patients undergoing percutaneous coronary intervention (PCI). 202 consecutive patients undergoing BVS implantation and platelet function testing were included. For investigating the impact of the Scaffold Surface on platelet reactivity, patients were stratified into two groups regarding the median BVS TSA. The on-treatment ADP-induced platelet reactivity was determined with the Multiplate analyzer and 30-day follow-up was available in 98% of patients. ADP-induced platelet aggregation values (median, [IQR]) did not differ between the two study groups (12.0 [9.0-19.0] U for patients with TSA > 1.39 cm(2) and 13.0 [9.0-19.5] U for patients with TSA ≤ 1.39 cm(2); p = 0.69). No correlation was observed between the BVS TSA and levels of platelet reactivity (Spearman rank correlation = -0.10, p = 0.16). At 30 days after PCI, two early STs (1%) were documented. Thus, in patients on a dual antiplatelet treatment regimen following BVS implantation, the extent of blood-to-BVS contact Surface does not negatively affect levels of on-treatment platelet reactivity.
-
IMPACT OF THE ABSORB BIORESORBABLE VASCULAR Scaffold Surface AREA ON ON-TREATMENT PLATELET REACTIVITY
Journal of the American College of Cardiology, 2015Co-Authors: Lisa Gross, Dirk Sibbing, Madeleine Eickhoff, Moritz Baquet, Martin Orban, Anne Krieg, Katarina Grujic, Hans D. Theiss, Stefan Brunner, Daniel TeupserAbstract:Bioresorbable vascular Scaffolds (BVS) promise to address pending issues of current-generation stents. While promising data of this novel platform is accumulating, signals of Scaffold thrombosis (ST) were noted in recent registry data. Our study aimed to determine whether such signals could be
